Compare Amgen, Inc. (AMGN) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Dropbox Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Dropbox Inc trades at $29.17 (market cap $6.81B). The key difference: Amgen, Inc. is far larger — about 28.8× Dropbox Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Dropbox Inc pays none. Which is the better fit depends on your goals.
| AMGN | DBX | |
|---|---|---|
Market Cap | $196.12B | $6.81B |
Sector | Health | Technology |
52-Week High | $388.16 | $32.17 |
52-Week Low | $271.18 | $22.06 |
Enterprise Value | $241.41B | $9.53B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DBX trades at $29.19, down 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $2.52 billion in 2025 with a net income margin of 20.16%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $900 million stock repurchase program and CEO transition plans announced in May 2026.
Outlook is mixed with strong profitability and consistent earnings beats offset by negative shareholder equity and high debt levels. The consensus price target of $30 suggests modest upside, but investors face risks from leadership changes and competitive pressures in cloud storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
